1Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the manage- ment of atrial fibrillation : The Task Force for the Management of Ari- al Fibrillation of the European Society of Cardiology ( ESC ) [ J ]. Eur Heart J, 2010, 31:2369 -2429.
2Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/ HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation [J]. Circulation, 2011, 123:e269 - e67.
3Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for tri- als in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA) [ J]. Eur Heart J, 2007, 28: 2803.
4Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC Guide- lines for the Management of Patients With Atrial Fibrillation [ J ]. Circulation, 2006, 114:700 - 752.
3Yamashita T,Koretsune Y,Yasaka M,et al.Randomized,multicenter,warfarin-controlled phase II study of edoxaban inJapanese patients with non-valvular atrial fibrillation[J].Circ J,2012,76(8):1840-1847.
4Mansur AP,Takada JY,Avakian SD,et al.Warfarin doses for anticoagulation therapy in elderly patients with chronicatrial fibrillation[J].Clinics(Sao Paulo),2012,67(6):543-546.
5Swets JA.ROC analysis applied to the evaluation of medical imaging techniques[J].Invest Radiol,1979,14(2):109-121.
6ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary.A Report of the American College of Cardiology/Ameriean Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Revise the 200l Guidelines for the Management of Patients With Atrial Fibrillation)[J].Circulation,2006,114(6):700-752.
7Suzuki S,Yamashita T,Kato T,et al.Incidence of major bleeding complication of warfarin therapy in Japanese atients with atrial fibrillation[J].Circ J,2007,71(7):761-765.
